Choosing a regulatory pathway for a new formulation: the four-question filter

Why pathway choice happens too late in most product launches

Pathway choice is usually an afterthought. A founder works with a manufacturer to land on a recipe, picks a label designer, and only then asks counsel whether the claims survive a regulatory read. By that point, the formula is committed, the bottle is committed, and the launch date is committed; the regulatory question collapses into a negotiation over what claims to scrub from the label, not a strategic decision about which pathway to use.

The earlier the four questions below are asked, the more optionality the operator preserves. A small adjustment to an ingredient list at the formulation stage can be the difference between a product that fits an established category with a clean pathway and a product that ends up in a residual category with onerous burdens. The cost of asking the questions early is one written memo. The cost of asking them late is a relaunch.

Question 1: What category does the finished product fall under?

The first question is taxonomic and binary at each branch. Is the product a food, a dietary supplement, a cosmetic, an over-the-counter monograph product, or a regulated therapeutic? In the United States, each of those is a distinct legal regime with distinct enforcement bodies, distinct registration regimes, and distinct labeling expectations. The answer is rarely as obvious as it sounds.

The category turns on intended use, the ingredients, the representations made on the label and in marketing, and sometimes on form factor. A topical that a brand calls a "serum" can be a cosmetic, an OTC monograph product, or a therapeutic depending on what the label claims it does. An oral product can be a food, a supplement, a beverage, or a therapeutic depending on the ingredient list and the claim language. The category is not a label decision; it is determined by the totality of the product.

Question 2: Is there a pre-market notification, registration, or approval requirement?

Once the category is provisionally identified, the second question is procedural. Does the regulator require a filing before the product can be sold? In some categories, the answer is no — the operator is responsible for compliance and the regulator inspects after the fact. In other categories, the answer is yes — a notification, a registration, or a full pre-market approval package must be on file before any commercial sale.

The cost and lead time of those filings vary by orders of magnitude. A facility registration is a few hours of paperwork. A new-ingredient notification is a months-long project requiring safety data and a written submission. A full pre-market approval is a multi-year program with clinical evidence requirements. The operator who learns about the requirement at launch is in a fundamentally different position than the one who learns at formulation.

Question 3: What labeling and claim restrictions apply?

The third question follows directly from the first two. Each category has a defined claim regime. Some categories permit only structure-function language: descriptions of the product's effect on the normal structure or function of the body. Other categories permit health-related claims under specific qualifying conditions. A small set permit therapeutic claims, but only after the pre-market approval question above has been answered with a filing.

The label is also more than the claim text. It is the ingredient declaration, the responsibility statement, the statement of identity, the contact information, the warnings section, and any required disclaimers. Each category has its own template for what each of those must say and how prominently. A label compliant in one category will be non-compliant in the next category over.

Question 4: What's the post-market surveillance burden?

Post-market is the longest-running cost in the regulatory equation, and the one most consistently underestimated. Some categories require a written adverse-event reporting program with defined timelines. Others require periodic renewal filings. Most require record-retention for defined periods, traceable batch records, and the ability to produce specifications and test results on request. The total annual cost of post-market compliance for a well-run program is real money — not the dominant line item, but a real one.

Operators who choose a category for the lighter pre-market burden sometimes inherit a heavier post-market burden than they expected. The right way to frame the choice is total regulatory cost across the product's lifecycle, not the cost of the next milestone alone.

The most common misclassification we see

The single most common misclassification is the product that is functionally one category but labeled and sold as another, usually for marketing reasons. A topical with a therapeutic claim sold as a cosmetic. A consumable with a health claim sold as a food. A branded product in a category whose ingredient list is fundamentally a different category's.

The misclassification rarely reads as deliberate; it accumulates in small steps. A claim added to the website after launch. A new variant that crosses a threshold. Marketing copy from a freelance writer that uses language outside the original review. The cumulative effect is a product that looks like one thing on the shelf and another thing on a regulator's desk. The fix is annual claims review, not a redesign at the first warning letter.

What this means for operators

• Ask the four questions before formulation freezes. The questions are cheap to answer in writing. They are expensive to answer at launch.
• Document the category decision in writing. A short internal memo naming the category, the governing regulation, and the basis for the choice is the artifact a regulator or counsel will ask for later.
• Match claims to category, not the other way around. If a claim is critical to the brand, the category must support it. Stretching a category to fit the claim is the path to enforcement.
• Budget for post-market, not just pre-market. Total regulatory cost is a multi-year line. The first year is rarely the biggest.
• Run an annual claims review. The product on launch day and the product eighteen months in are different products in marketing terms. Make sure they are the same product in regulatory terms.